Loading...
XNASGMAB
Market cap12bUSD
Dec 20, Last price  
20.31USD
1D
1.10%
1Q
-20.45%
Jan 2017
22.48%
Name

Genmab A/S

Chart & Performance

D1W1MN
XNAS:GMAB chart
P/E
2.13
P/S
0.56
EPS
68.51
Div Yield, %
0.00%
Shrs. gr., 5y
1.22%
Rev. gr., 5y
40.35%
Revenues
16.47b
+12.87%
4,101,00098,505,000135,547,000529,537,000745,113,000586,076,000582,077,000350,936,000484,636,000663,570,000850,385,0001,133,041,0001,816,122,0002,365,436,0003,025,137,0005,366,000,00010,111,000,0008,482,000,00014,595,000,00016,474,000,000
Net income
4.35b
-20.18%
-415,212,000-393,590,000-438,236,000-383,369,000-965,089,000-1,010,760,000-321,456,000-596,368,000-487,118,000112,362,000301,296,000763,513,0001,187,075,0001,103,551,0001,472,141,0002,166,000,0004,758,000,0002,957,000,0005,452,000,0004,352,000,000
CFO
7.38b
+88.65%
-367,698,000-208,644,000-379,623,000505,898,000-513,333,000-570,061,000268,171,000-437,225,00070,919,000-127,999,000132,671,000311,449,000327,719,0001,588,972,0001,014,786,0001,326,000,0006,433,000,0002,228,000,0003,912,000,0007,380,000,000
Earnings
Feb 12, 2025

Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
URL
https://www.genmab.com/
IPO date
Oct 01, 2000
Employees
2,015
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
16,474,000
12.87%
14,595,000
72.07%
8,482,000
-16.11%
Cost of revenue
7,856,000
5,562,000
4,181,000
Unusual Expense (Income)
NOPBT
8,618,000
9,033,000
4,301,000
NOPBT Margin
52.31%
61.89%
50.71%
Operating Taxes
1,285,000
1,513,000
975,000
Tax Rate
14.91%
16.75%
22.67%
NOPAT
7,333,000
7,520,000
3,326,000
Net income
4,352,000
-20.18%
5,452,000
84.38%
2,957,000
-37.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
(564,000)
(628,000)
(312,000)
BB yield
0.40%
0.03%
0.02%
Debt
Debt current
90,000
74,000
62,000
Long-term debt
1,450,000
1,120,000
788,000
Deferred revenue
480,000
487,000
Other long-term liabilities
515,000
11,000
13,000
Net debt
(26,729,000)
(21,263,000)
(18,859,000)
Cash flow
Cash from operating activities
7,380,000
3,912,000
2,228,000
CAPEX
(376,000)
(317,000)
(252,000)
Cash from investing activities
(1,282,000)
(2,761,000)
(961,000)
Cash from financing activities
(606,000)
(789,000)
(420,000)
FCF
8,654,000
4,761,000
2,696,000
Balance
Cash
28,135,000
22,324,000
19,338,000
Long term investments
134,000
133,000
371,000
Excess cash
27,445,300
21,727,250
19,284,900
Stockholders' equity
19,149,000
15,132,000
10,167,000
Invested Capital
13,746,000
13,397,000
12,954,000
ROIC
54.03%
57.08%
25.92%
ROCE
26.20%
31.66%
18.60%
EV
Common stock shares outstanding
65,915
660,096
660,458
Price
2,155.00
-26.73%
2,941.00
11.83%
2,630.00
6.78%
Market cap
142,046,189
-92.68%
1,941,342,454
11.76%
1,737,003,251
7.04%
EV
115,317,189
1,920,079,454
1,718,144,251
EBITDA
8,913,000
9,395,000
4,549,000
EV/EBITDA
12.94
204.37
377.70
Interest
27,000
21,000
13,000
Interest/NOPBT
0.31%
0.23%
0.30%